UniProt Q96RG2 · PDB · AlphaFold · Substrate: ZIPtide · Clone: Catalytic (aa 879-1323)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 88.3% | 11.7% | 91.48 | 0.563 |
| 2 | Abrocitinib | 31.1% | 68.9% | 99.50 | 0.581 |
| 3 | Darovasertib | 27.5% | 72.5% | 96.99 | 0.719 |
| 4 | Avapritinib | 21.8% | 78.2% | 97.73 | 0.644 |
| 5 | Ponatinib | 19.7% | 80.3% | 78.23 | 0.534 |
| 6 | Alectinib | 17.3% | 82.7% | 95.49 | 0.651 |
| 7 | Ceritinib | 14.5% | 85.5% | 95.44 | 0.618 |
| 8 | Crizotinib | 13.8% | 86.2% | 91.39 | 0.581 |
| 9 | Zanubrutinib | 13.6% | 86.4% | 98.24 | 0.788 |
| 10 | Mitapivat | 13.5% | 86.5% | 100.00 | 0.625 |
| 11 | Midostaurin | 13.1% | 86.9% | 78.64 | 0.500 |
| 12 | Capivasertib | 12.4% | 87.6% | 96.48 | 0.644 |
| 13 | Capmatinib | 11.7% | 88.3% | 99.75 | 0.582 |
| 14 | Neratinib | 11.2% | 88.8% | 93.18 | 0.597 |
| 15 | Canertinib | 8.8% | 91.2% | 96.49 | 0.671 |
| 16 | Defactinib | 8.7% | 91.3% | 92.68 | 0.450 |
| 17 | Selumetinib | 8.7% | 91.3% | 100.00 | 0.640 |
| 18 | Tivozanib | 8.3% | 91.7% | 92.42 | 0.673 |
| 19 | Tepotinib | 8.3% | 91.7% | 99.75 | 0.727 |
| 20 | Netarsudil | 8.2% | 91.8% | 93.22 | 0.676 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 2.56
- Epithelial log2(TPM+1): 3.72
- Fold change: -1.16
- Status: Downregulated
Selectivity landscape vs inhibition on PASK
Each point is one of the 92 approved drugs; color = inhibition % on PASK.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…